LONDON, May 6, 2014 /PRNewswire/ --
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
http://www.investor-edge.com/2168-register
Celgene Corp.'s stock recorded a trading volume of 2.20 million shares on Monday, below its three months average volume of 3.80 million shares. The stock finished the day at $148.36, which was 0.65% higher its previous day's closing of $147.40. The stock registered an intraday range of $143.85 and $148.72 during the trading session. Shares in Celgene Corp. have advanced 0.92% in the previous three trading sessions and 7.99% in the last one month. However, the stock has declined 12.20% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $148.77 is below its 200-day moving average of $152.59. Celgene Corp.'s stock traded at a PE ratio of 31.43 and has a Relative Strength Index (RSI) of 53.77. Sign up today to read free research on CELG at:
http://www.investor-edge.com/2168-CELG-06May2014.pdf
On Monday, shares in Cell Therapeutics Inc. finished Monday's session 2.36% higher at $3.03. A total of 1.60 million shares were traded, much below its three months average volume of 4.37 million shares. The stock moved between $2.90 and $3.04 during the session. Shares in Cell Therapeutics Inc. have gained 2.71% in the previous three trading sessions and 58.64% from the beginning of 2014, while it has fallen by 8.46% in the last one month. The company's shares are trading below their 50-day moving average. The stock's 50-day moving average of $3.47 is above its 200-day moving average of $2.30. Further, the company's stock has an RSI of 39.66. Sign up today to read free research on CTIC at:
http://www.investor-edge.com/2168-CTIC-06May2014.pdf
On Monday, Geron Corp.'s stock fluctuated between $1.79 and $1.90 before ending the session 1.62% higher at $1.88. The company's stock reported a trading volume of 2.12 million shares on Monday, much below its three months average volume of 5.57 million shares. Over the previous three trading sessions and in the last one month, shares in Geron Corp. have fallen by 5.05% and 3.09%, respectively. Also, the stock has lost 60.34 % on YTD basis. The company's shares are trading below their 50-day and 200-day moving averages of $2.72 and $3.43, respectively. Moreover, the company's shares have an RSI of 37.61. Sign up today to read free research on GERN at:
http://www.investor-edge.com/2168-GERN-06May2014.pdf
Shares in BioMarin Pharmaceutical Inc. gained 4.21% on Monday, closing the day at $60.13. The stock recorded a trading volume of 1.91 million shares, above its three months average volume of 1.76 million shares. The stock oscillated between $57.22 and $60.23 during the session. BioMarin Pharmaceutical Inc.'s shares have gained 3.26% in the previous three trading sessions. However, the stock has declined 5.07% in the last one month and 14.53% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages of $69.84 and $68.62, respectively. Furthermore, the company's stock has an RSI of 37.00. Sign up today to read free research on BMRN at:
http://www.investor-edge.com/2168-BMRN-06May2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
